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DRUG PRICE AND UTILIZATION OF BETA BLOCKERS IN US
MEDICAID PROGRAMS
Jing Y, Chen Y,Wigle PR, Guo JJ
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: Beta-blockers (BB) were the ﬁfth most widely pre-
scribed class of medications in 2004. They are commonly used
for patients with high blood pressure, angina, tachyarrhythmia,
and congestive heart failure. The objective of this study was to
analyze the drug price trends of brand-name and generic beta
blockers, and to assess drug utilization and market-share com-
petition in US Medicaid Programs. METHODS: The monthly
average wholesale price (AWP) per daily dose for each antihy-
pertensive beta-blocker available between 1986 and 2002 was
evaluated using data extracted from First DataBank. National
Medicaid pharmacy data ﬁles were also analyzed to construct
the quarterly prescription numbers and per-prescription reim-
bursement ﬁgures for each drug in the time frame of 1990
through 2004. The market-share of beta-blockers was calculated
based on numbers of prescriptions. RESULTS: Since 1993, the
average AWP for brand-name drugs increased over time, while
generic drug prices decreased or changed slightly. The only
exception was propranolol. Reimbursement cost per prescription
showed a similar pattern. The expenditure for BBs in US Med-
icaid programs in 2003 was $206 million (114.8 million for
brand-name drugs, 91.6 million for generics). While the market
share of brand-name BB prescriptions dropped from 63.1% in
1991 to 25.5% in 2003, Toprol prescriptions has increased
sharply to 870,037 in 2nd quarter 2004 since entry to the market
in early 1992. The prescriptions for Tenormin and Lopressor
decreased over time due to availability of generic products. The
prescriptions of atenolol and metoprolol increased sharply after
they were introduced into the market. CONCLUSIONS: Large
increases in BB expenditures paralleled the increased number of
prescriptions. The increased use of BB might be due to the blood
pressure beneﬁt for diabetic patients and mortality beneﬁt for
post-MI patients with heart failure. The market share competi-
tion between brand-name and generic drugs was observed in U.S.
Medicaid programs.
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DRUG PRICE AND UTILIZATION OF ACE INHIBITORS IN US
MEDICAID POPULATION
Li X, Jing Y, Guo JJ,Wigle PR, Chen Y, Kelton CM
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OBJECTIVES: Angiotensin-converting-enzyme inhibitors
(ACEIs) are used by millions of Americans to treat high blood
pressure, heart failure, and kidney disease. The objective of this
study was to analyze the drug price trends of ACEIs, and to
assess drug utilization and market-share competition in US Med-
icaid Programs. METHODS: The monthly average wholesale
price (AWP) per daily antihypertensive dose for each ACEI was
evaluated using data extracted from the First DataBank. Data
for ACEIs available between 1989 and 2002 were assessed.
National Medicaid pharmacy data ﬁles were also analyzed to
construct the quarterly prescription numbers and per-
prescription reimbursement ﬁgures for each drug from 1991
through 2004. The market-share of ACEIs was calculated based
on proportion of numbers of prescriptions. RESULTS: The
average AWP per daily antihypertensive dose for brand-name
drugs increased over time, while the AWP for generically avail-
able ACEIs decreased dramatically after being introduced into
the market. The AWP per daily dose for Prinivil, Vasotec, Zestril
were approximately $2 to $2.50 and relatively higher than other
ACEIs. The average reimbursement per prescription for brand-
name ACEIs in Medicaid increased from $33.30 in 1991 to
$49.30 in 2004. The average reimbursement per ACEI generic
prescription in Medicaid decreased from $34.00 in 1996 to
$24.60 in 2004. The market share of brand-name ACEI pre-
scriptions dropped from 100% in 1991 to 20% in 2004. After
generic ACEIs became available, brand-name prescriptions
decreased dramatically. The generic market share took over the
brand-name market share in 2003 due to the increasing use of
lisinopril and enalapril. CONCLUSIONS: Generically available
ACEI AWP and reimbursement prices decreased due to compe-
tition, but there was little impact on brand-name reimbursement
prices. The market share competition between brand-name and
generic drugs was observed in Medicaid programs. Decreased
use of brand-name ACEIs might be due to Medicaid policy of
generic substitution when available.
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PRESCRIPTION DRUG INSURANCE STATUS AND
UTILIZATION OF ANTI-HYPERLIPIDEMICS: RESULTS FROM
THE 2000 MEDICAL EXPENDITURE PANEL SURVEY
Gupta K, Cline R
University of Minnesota, Minneapolis, MN, USA
OBJECTIVES: Health insurance instability is a prevalent phe-
nomenon in the United States. A large number of studies provide
evidence that health insurance instability affects healthcare uti-
lization. However, none of the studies have looked at the speciﬁc
effect of prescription drug insurance instability on the use of
drugs for chronic conditions like hyperlipidemia. Therefore, the
objective of this study was to describe the association between
prescription drug insurance instability and the access of anti-
hyperlipidemics among people aged 18 to 64 years. METHODS:
The data for this study was obtained from the 2000 Medical
Expenditure Panel Survey, a nationally representative survey of
healthcare use and spending in the U.S. civilian, non-institution-
alized population. Complete prescription drug coverage data was
obtained by combining data from the private prescription drug
insurance variable and several health insurance variables repre-
senting programs that frequently, or nearly always, include pre-
scription coverage. Medical Conditions (MEPS:HC-052) and
Prescribed Medicines (MEPS:HC-015A) ﬁles were used to gen-
erate information about this disease condition and events of anti-
hyperlipidemic access respectively. RESULTS: The 2000 MEPS
contained 14,223 respondents between the ages 18–64 with suf-
ﬁcient insurance information throughout the year. Among this
age group, 740 people reported to have hyperlipidemia whereas
only 230 (31.1%) reported purchasing any anti-hyperlipidemics.
Among the people who had purchased any anti-hyperlipidemics
during the year 2000, 183 (79.57%), 35 (15.22%) and 12
(5.22%) had continuous drug insurance, unstable insurance and
no drug insurance throughout the year respectively. The associ-
ation between drug insurance statuses and acquisition of any
lipid lowering agent was statistically signiﬁcant at p < 0.05 after
controlling for demographics, socio-economic and employment
characteristics. CONCLUSION: As in previous studies of insur-
ance instability, there appears to be an association between anti-
hyperlipidemic access and prescription insurance status of an
individual. Similar studies are required for other chronic condi-
tions like hypertension and diabetes.
